Drug intelligence / Profile preview

G2202

Development stage: Preclinical
Lead developer: BCWorld Pharma
Modality: Small Molecules
Administration: Oral

Overview

G2202 is a small molecule therapeutic candidate being developed by BCWorld Pharma for the treatment of neuropathic pain. The drug is formulated as an orally disintegrating tablet (ODT), leveraging the company's proprietary drug delivery systems (DDS) to improve patient compliance and ease of administration, particularly for those who have difficulty swallowing conventional tablets. As of 2024, G2202 is in the preclinical stage, specifically undergoing formulation research to optimize its delivery profile for neuropathic pain management.

Beyond the preview

Go deeper on G2202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G2202.

Explore the full profile